Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

THRV-1268

PreclinicalSmall molecule

TThryv Therapeutics, Inc.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long QT SyndromeRecruiting

Long QT SyndromePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Long QT Syndrome

NCT07277582

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

Completed·TThryv Therapeutics, Inc.·Phase 1·NCT07186946·16 enrolled

ESS1 trial

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

Completed·TThryv Therapeutics, Inc.·Phase 1·NCT06507839·56 enrolled

Long QT Syndrome1 trial

A Phase 2/3, Two-part, Dose-ranging, Adaptive Study to Evaluate Efficacy and Safety of THRV-1268 in Participants Diagnosed With Long QT Syndrome Type 2 (LQTS 2)

Recruiting·TThryv Therapeutics, Inc.·Preclinical·NCT07277582·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for THRV-1268. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — THRV-1268 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for THRV-1268. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thryv Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThryv Therapeutics, Inc.

Related News